Pirfenidone: an update on clinical trial data and insights from everyday practice
Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonary fibrosis in the European Union based on the results of two pivotal phase III, double-blind, random...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 March 2014
|
| In: |
European respiratory review
Year: 2014, Jahrgang: 23, Heft: 131, Pages: 111-117 |
| ISSN: | 1600-0617 |
| DOI: | 10.1183/09059180.00008513 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/09059180.00008513 Verlag, lizenzpflichtig, Volltext: https://err.ersjournals.com/content/23/131/111 
|
| Verfasserangaben: | Michael Kreuter |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 173874373X | ||
| 003 | DE-627 | ||
| 005 | 20220819024223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201116s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/09059180.00008513 |2 doi | |
| 035 | |a (DE-627)173874373X | ||
| 035 | |a (DE-599)KXP173874373X | ||
| 035 | |a (OCoLC)1341376423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 245 | 1 | 0 | |a Pirfenidone |b an update on clinical trial data and insights from everyday practice |c Michael Kreuter |
| 264 | 1 | |c 1 March 2014 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.11.2020 | ||
| 520 | |a Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonary fibrosis in the European Union based on the results of two pivotal phase III, double-blind, randomised, placebo-controlled clinical trials (CAPACITY) demonstrating efficacy and safety, and supported by two Japanese clinical trials (SP2 and SP3). Currently, there is increasing interest in experience with pirfenidone in patients relating to the real-world setting. - Following the publication of the CAPACITY clinical studies, additional analyses have been conducted to provide further support for pirfenidone in clinical practice, including a modified per-protocol analysis of the CAPACITY study population. New data from the RECAP extension study also provided longer term data for pirfenidone and promising continuation rates with treatment. Pirfenidone is also being evaluated in specialist centre cohorts providing important information on real-world efficacy and safety. Increasing experience with pirfenidone in everyday clinical practice is helping to establish \expert guidance on the management of known adverse events, together with practical recommendations, to ensure adherence to treatment so that the possible longer term benefits of pirfenidone treatment in reducing lung function decline can be maximised. | ||
| 773 | 0 | 8 | |i Enthalten in |t European respiratory review |d Sheffield : Soc., 2005 |g 23(2014), 131, Seite 111-117 |h Online-Ressource |w (DE-627)500021430 |w (DE-600)2202947-3 |w (DE-576)281286477 |x 1600-0617 |7 nnas |a Pirfenidone an update on clinical trial data and insights from everyday practice |
| 773 | 1 | 8 | |g volume:23 |g year:2014 |g number:131 |g pages:111-117 |g extent:7 |a Pirfenidone an update on clinical trial data and insights from everyday practice |
| 856 | 4 | 0 | |u https://doi.org/10.1183/09059180.00008513 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://err.ersjournals.com/content/23/131/111 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201116 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN173874373X |e 3804285473 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"an update on clinical trial data and insights from everyday practice","title_sort":"Pirfenidone","title":"Pirfenidone"}],"id":{"doi":["10.1183/09059180.00008513"],"eki":["173874373X"]},"name":{"displayForm":["Michael Kreuter"]},"physDesc":[{"extent":"7 S."}],"origin":[{"dateIssuedKey":"2014","dateIssuedDisp":"1 March 2014"}],"relHost":[{"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Respiratory Society"}],"id":{"issn":["1600-0617"],"eki":["500021430"],"zdb":["2202947-3"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Nachgewiesen 14.2005 - ; auch mit durchgehender Nr.-Zählung"],"note":["Gesehen am 31.10.24"],"part":{"issue":"131","volume":"23","pages":"111-117","year":"2014","extent":"7","text":"23(2014), 131, Seite 111-117"},"recId":"500021430","language":["eng"],"disp":"Pirfenidone an update on clinical trial data and insights from everyday practiceEuropean respiratory review","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Sheffield","dateIssuedKey":"2005","dateIssuedDisp":"2005-","publisher":"Soc."}],"name":{"displayForm":["European Respiratory Society"]},"title":[{"title":"European respiratory review","title_sort":"European respiratory review"}]}],"person":[{"family":"Kreuter","given":"Michael","roleDisplay":"VerfasserIn","role":"aut","display":"Kreuter, Michael"}],"language":["eng"],"note":["Gesehen am 16.11.2020"],"recId":"173874373X","type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a KREUTERMICPIRFENIDON1201 | ||